Fibrosis index nine superiority for cirrhosis in hypopituitarism: Clinical validation of endocrine liver triage tool

Table 1 Baseline characteristics of patients in the cirrhosis and non-cirrhosis groups

Variable	Cirrhosis group (n = 19)	Non-cirrhosis group (n = 16)	P value
Female sex	8 (42.1)	5 (31.3)	0.727
Age (year)	28 (20, 34)	19.5 (16, 23.5)	0.024a
Height (m)	1.78 (1.58, 1.81)	1.71 (1.60, 1.78)	0.233
Weight (kg)	87 (62, 101)	69.48 (62.13, 88.75)	0.304
BMI (kg/m2)	27.76 (23.86, 30.84)	24.71 (22.08, 28.89)	0.849
Etiology			0.537
CP	8 (42.1)	10 (62.5)
PSIS	7 (36.8)	4 (25)
Germ cell tumor	4 (21.1)	2 (12.5)
TH replacement	19 (100)	16 (100)	1
FT4 (ng/dL)	1.09 (0.96, 1.23)	1.33 (1.10, 1.44)	0.444
TSH (mIU/L)	0.032 (0.011, 0.143)	0.01 (0.008, 0.042)	0.939
Glucocorticoid replacement	18 (94.7)	14 (87.5)	0.742
Peak Cortisol (μg/dL)	0.5 (0.5, 0.6)	1.65 (0.5, 7.55)	0.080
GH replacement	12 (63.2)	8 (50)	0.547
IGF-1 (ng/mL)	72.5 (24.5, 110.5)	55 (41, 123)	0.757
Gonadal hormone replacement	9 (47.4)	10 (62.5)	0.486
T (ng/mL)1	2.79 (0.1, 3.33; n = 11)	1.45 (0.1, 2.54; n = 11)	0.270
E2 (pg/mL)2	< 15 (n = 8)	15 (15, 79.5; n = 5)	0.097

^aP < 0.05.

¹Reported for male patients only.

²Reported for female patients only.

Data are presented as median (interquartile range) for continuous variables and as n (%) for categorical variables. All values are based on non-missing data unless otherwise indicated. BMI: Body mass index; CP: Craniopharyngioma; PSIS: Pituitary stalk interruption syndrome; TH: Thyroid hormone; FT4: Free thyroxine; TSH: Thyroid-stimulating hormone; GH: Growth hormone; IGF-1: Insulin-like growth factor 1; T: Testosterone; E2: Estradiol.

Table 2 Liver-related parameters and non-invasive fibrosis scores in the cirrhosis and non-cirrhosis groups

Variable	Cirrhosis group (n = 19)	Non-cirrhosis group (n = 16)	P value
Diabetes	7 (36.8)	0 (0)	0.003b
AST (IU/L)	53 (35.5, 63)	32 (26.75, 50)	0.033a
ALT (IU/L)	36 (23, 63)	27.5 (15, 55.25)	0.417
GGT (IU/L)	85 (58, 176)	26 (16, 44.25)	< 0.0001c
ALP (IU/L)	108 (82, 205)	121 (70, 205)	0.938
Alb (g/L)	46 (40, 48)	47.5 (46, 49)	0.109
INR	1.09 (1.05, 1.16)	1.02 (0.99, 1.07)	0.027a
Bilirubin (μmol/L)	13.6 (10.6, 25)	10.9 (9.33, 17.68)	0.066
Platelet (G/L)	102 (58, 183)	255 (217.8, 320)	< 0.0001c
HA (ng/mL)	157.5 (92, 247.8; n = 18)	63 (40.5, 87.75; n = 14)	0.0002c
PIIINP (ng/mL)	16 (9.3, 26.25; n = 18)	16 (9, 23; n = 15)	0.800
CIV (ng/mL)	136 (103.8, 176.8; n = 18)	81 (50, 106; n = 15)	0.0003c
LN (ng/mL)	163.5 (105, 196.8)	122 (100, 156; n = 15)	0.100
FIB-4	2.15 (1.20, 4.05)	0.48 (0.34, 0.75)	< 0.0001c
APRI	1.05 (0.59, 2.17)	0.34 (0.27, 0.4)	< 0.0001c
FIB-9	3.75 (1.89, 3.99)	0.49 (0.02, 1.61)	< 0.0001c
LSM (kPa)	23.2 (15.8, 31.9; n = 15)	5.7 (3.9, 6.8; n = 5)	0.0001c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Data are presented as median (interquartile range) for continuous variables and as n (%) for categorical variables. All values are based on non-missing data unless otherwise indicated. Alb: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; INR: International normalized ratio; HA: Hyaluronic acid; PIIINP: Procollagen III N-terminal peptide; CIV: Type IV collagen; LN: Laminin; FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-9: Fibrosis-9; LSM: Liver stiffness measurement.